News News Select Year All Years 2026 (16) 2025 (34) 2024 (29) 2023 (30) 2022 (33) 2021 (27) 2020 (34) 2019 (32) 2018 (42) 2017 (35) 2016 (43) 2015 (53) 2014 (26) 2013 (21) 2012 (16) 2011 (6) 2010 (4) 2009 (5) 2007 (1) 2006 (1) Search News Found 488 Results Page 43 of 49« First«...102030...4142434445...»Last » May 13, 2014 DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children May 12, 2014 DBV Technologies to Host and Webcast Investor Day in New York City on May 21, 2014 April 17, 2014 DBV Technologies publishes its 2013 Registration Document and its 2013 Annual Financial Report April 16, 2014 DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy (EPITTM) with Viaskin® at the French Congress of Allergy April 16, 2014 CFA 2014 – Clinical Abstract April 15, 2014 DBV Technologies Announces Topline Financial Results for First Three Months 2014 April 9, 2014 DBV Technologies and CEA conclude a scientific cooperation to investigate epigenetic modulation in epicutaneous immunotherapy April 7, 2014 DBV Technologies Announces Creation of US Subsidiary and Appoints Ms. Susanna Mesa as Vice President of Finance, US Investor Relations & Strategy March 31, 2014 Additional Contribution to the Liquidity Agreement with Natixis March 25, 2014 DBV Announces Data Presentations for EPIT at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2014 Page 43 of 49« First«...102030...4142434445...»Last »
